SARMsEarly clinical development

PF-06260414

PF-06260414 is true sarm candidate. The evidence base is early clinical development, and it is not an FDA-approved bodybuilding product.

Last reviewed: 2026-08-09Aliases: PF-06260414
Safety context

Recreational SARM use has clinically important uncertainties and documented adverse events.

Regulatory / research statusInvestigational/unapproved.

At a glance

  • Classification: True SARM candidate
  • Evidence: Early clinical development
  • Status: Investigational/unapproved.

What it is

Selective androgen receptor modulators are androgen-receptor ligands developed to seek tissue-selective anabolic effects. “Selective” does not mean side-effect free, and the degree of tissue selectivity seen in animals does not necessarily translate cleanly to humans.

Research

Clinical development across the SARM class has focused on conditions such as muscle wasting, sarcopenia, and selected cancers. Some candidates increased lean mass in trials, but functional benefits have been inconsistent and no conclusion about recreational safety follows from short controlled studies.

Safety

Human reports and trials have documented concerns including liver-enzyme elevations or drug-induced liver injury, adverse lipid changes, suppression of endogenous sex-hormone signaling, and other compound-specific adverse events. Long-term recreational exposure remains poorly characterized.

Regulatory and product-quality issues

FDA states that SARMs marketed to consumers are unapproved drugs rather than legal dietary supplements. Products sold online may be mislabeled, substituted, or contain undeclared active ingredients.

References

  1. Systematic review of SARM safety (PubMed)
This page is an educational reference, not individualized medical advice. Inclusion of a compound is not endorsement. LiftLab does not provide nonmedical cycles, stacks, sourcing, injection instructions or personalized dosing.

Share with